Providence Medical wins FDA nod for Corus navigation system with Medtronic StealthStation
Providence Medical Technology announced today that the FDA cleared the use of its Corus navigation access system for use in spinal surgery. Pleasanton, California-based Providence’s system provides navigation for its Corus Spinal System during spinal surgery. The company designed it to specifically work with the Medtronic StealthStation for posterior spinal fusion procedures.
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced positive updated safety and efficacy data from its first-in-human study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or […]
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial that demonstrate the company’s lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF) […]
Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines
Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.
Secondary Spotlight ‘The most important letters in PE are D-P-I’: Gerald Cooper on the 2024 Secondary Market Landscape Revelation Partners caught up with Gerald Cooper, Head of the North America Secondary Advisory Practice at Campbell Lutyens, to discuss the 2024 fundraising and exit environment, the evolution of the GP-led secondary market, and considerations for GPs […]
VC Secondary Market Partner Perspectives: Mike Boggs
In this fifth (and final) release in a series of interviews with successful figures in the venture capital secondary market, Derek Minno talks with Mike Boggs, a co-founder of Revelation Partners, which manages over $1.5 billion, making the firm the largest dedicated provider targeting healthcare secondaries. This article features Derek’s takeaways from the conversation along […]
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of RejoynTM, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared RejoynTM (developed as CT-152), the first prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years […]
Hildred Capital Raises $750 Million Continuation Fund
Private-equity firm Hildred Capital Management has closed its first continuation fund to extend its ownership of two consumer-healthcare businesses and inject them with more money for growth.
Nouscom extends Series C round to $82m for cancer vaccine trials
Immuno-oncology company Nouscom has extended a Series C financing round to raise $82m (€75.8m) as it looks to advance its pipeline of personalised and off-the-shelf cancer vaccines. An additional $7.6m was added from Italian venture capital firm Angelini Ventures, joining the round which was first announced in November 2023. The oversubscribed round adds to a Series […]
Mission Therapeutics raises £25.2m to enhance power of mitochondria
Clinical-stage biotech Mission Therapeutics has raised £25.2 million to progress clinical development of its mitophagy clinical candidates.